Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?

STUDY OBJECTIVES: The safety profile of the dual orexin receptor antagonists (DORAs) are currently unknown with regard to nocturnal responsivity among people with insomnia. We compared the auditory awakening thresholds (AATs) of the DORA suvorexant (10 and 20 mg) versus placebo in 12 individuals wit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Sleep Med
Hlavní autoři: Drake, Christopher L., Kalmbach, David A., Cheng, Philip, Roth, Thomas, Tran, Kieulinh Michelle, Cuamatzi-Castelan, Andrea, Atkinson, Rachel, Singh, Meeta, Tonnu, Christine V., Fellman-Couture, Cynthia
Médium: Artigo
Jazyk:Inglês
Vydáno: American Academy of Sleep Medicine 2019
Témata:
Scientific Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6760418/
https://ncbi.nlm.nih.gov/pubmed/31538599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.7920
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky